Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, posted on LinkedIn:
“Over the past decade, we’ve been using the same first-line treatment strategy for HER2+ metastatic breast cancer: CLEOPATRA
Induction taxane/HP followed by dual HER2 blockade maintenance.
We did however fine-tune this regimen:
– PERUSE unlocked the use of a better tolerated paclitaxel induction backbone
– EMERALD offered an alternative eribulin backbone
– PATINA introduced the concept of CDK4/6i (palbociclib) maintenance. We’re now on the verge of a paradigm switch: with DB09 expected to report soon, the HER2 ADC trastuzumab deruxtecan (T-DXd) may replace CLEOPATRA, at least for some patients.
The hope: to cure more patients from their metastatic HER2+ disease.
The challenge: ensuring a good quality of life for patients that face years of systemic treatment.
And preventing/mitigating ILD, which remains a life-threatening risk with T-DXd.”